Metronidazol Actavis

Metronidazole, the active ingredient in Metronidazol Actavis, is a nitroimidazole antibiotic presented as an oral tablet for systemic use. It is indicated for the treatment of infections caused by anaerobic bacteria and susceptible protozoa, including bacterial vaginosis, trichomoniasis, amoebiasis, giardiasis, and Clostridioides difficile infection in adult and adolescent patients.

GNH USA supplies Metronidazol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product quality, regulatory compliance and reliable global logistics. The company adheres to stringent quality standards and provides comprehensive technical support to its customers.

Metronidazole is a nitroimidazole antibiotic that targets anaerobic bacteria and protozoal organisms.

- Bacterial vaginosis: eliminates the overgrowth of anaerobic bacteria, restoring normal vaginal flora. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving genital symptoms. - Amoebiasis: clears intestinal Entamoeba histolytica infection, preventing dysentery. - Giardiasis: treats Giardia lamblia infection, reducing diarrhea and malabsorption. - Anaerobic bacterial infections: combats susceptible anaerobic bacteria in various body sites, aiding infection control. - Clostridioides difficile infection: reduces toxin‑producing C. difficile, helping resolve colitis.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often occurring early in therapy. - Metallic taste: a transient metallic sensation in the mouth. - Diarrhea: loose stools that may be self‑limiting. - Headache: mild to moderate headache without focal signs.

Serious or Rare Side Effects: - Seizures: rare central nervous system excitation leading to convulsions. - Peripheral neuropathy: numbness or tingling in extremities that may be irreversible. - Severe allergic reactions: including Stevens‑Johnson syndrome, toxic epidermal necrolysis, or anaphylaxis.

Before prescribing Metronidazol Actavis, clinicians should consider several safety precautions.

- Assess renal function: dose adjustment may be required in patients with impaired kidney function. - Avoid alcohol: concurrent intake can cause a disulfiram‑like reaction with flushing and tachycardia. - Use caution in pregnancy: weigh potential benefits against risks, as safety data are limited. - Monitor for allergic reactions: discontinue if rash, swelling, or signs of hypersensitivity develop. - Discontinue if severe neurotoxicity occurs: stop treatment if seizures or peripheral neuropathy appear. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Metronidazol Actavis can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause a disulfiram‑like reaction with severe flushing, nausea and hypotension. - Warfarin: potentiates anticoagulant effect, increasing risk of bleeding. - Lithium: can raise lithium serum levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy, requiring additional contraceptive measures. - Cimetidine: can increase metronidazole plasma concentrations, enhancing side effects. - Theophylline: may raise theophylline levels, necessitating monitoring for toxicity.